DOCS
Doximity, Inc.
DOCS
Doximity, Inc.
Doximity delivered strong fiscal Q1 2027 results, validating my prior bullish stance on valuation and AI-driven growth. The stock surged over 30% intraday, reflecting the market's recognition of DOCS'
Doximity NYSE: DOCS reported fiscal 2027 first-quarter revenue of $157 million, up 7% from a year earlier, as the company cited improving demand from pharmaceutical and hospital customers and increase
Doximity had a solid first quarter and raised its full year revenue guidance. But AI search isn't baked into these forecasts, analysts believe, and it's bringing in 10 times the revenue it costs to ru
Doximity, Inc. is upgraded to buy as the narrative shifts from stagnation to credible reacceleration, driven by AI engagement and improved revenue guidance. Revenue grew 7% YoY to $156.6M, with FY27 g
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible